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Abstract Activation of transcription factor NF-UB is accom-
plished by degradation of its inhibitor IUBK. Signal induced
phosphorylation of IUBK on serine 32 and 36 targets the protein
for ubiquitination on lysine 21 and 22. Here we use a
phosphorylated peptide substrate representing residues 20^43 of
IUBK to investigate requirements for ubiquitination of IUBK.
Phosphorylation dependent polyubiquitination is carried out by a
multiprotein complex containing LTrCP, Skp1 and Cdc53
(Cul1). In the presence of ubiquitin activating enzyme and the
protein complex containing LTrCP, polyubiquitination of IUBK
peptide was dependent on the presence of Cdc34, while Ubc5 only
stimulated mono- and di-ubiquitination.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
In unstimulated cells the transcription factor NF-UB is held
in the cytoplasm, in a form that is unable to bind DNA, by
IUBK. Exposure of cells to a wide variety of stimuli results in
release of the transcription factor from IUBK allowing the
active DNA binding form of the NF-UB to translocate to
the nucleus where it binds to its recognition sites in the up-
stream regions of a wide variety of genes. The NF-UB family
of proteins share a conserved region known as the Rel homol-
ogy domain (RHD) which contains the nuclear localisation
signal (NLS), as well as the dimerisation and DNA binding
functions. Typically, the NF-UB form activated by extracellu-
lar signals is composed of p50 and p65. Inhibitor IUB proteins
contain ankyrin repeat domains and association with NF-UB
not only occludes the nuclear localisation sequence of p50 and
p65 leading to cytoplasmic sequestration, but also prevents
NF-UB/DNA binding activity. Following signal induction
IUBK is rapidly phosphorylated and degraded [1^3]. Released
NF-UB translocates from the cytoplasm to the nucleus where
it activates responsive genes. As the promoter for IUBK is NF-
UB dependent, IUBK mRNA levels rise and IUBK protein is
rapidly resynthesised. At this stage cytoplasmic levels of NF-
UB are low and free IUBK translocates to the nucleus where it
terminates NF-UB dependent transcription. This is accom-
plished by inhibition of the NF-UB/DNA interaction and ex-
port of the NF-UB/IUBK complex back to the cytoplasm [4,5].
Sites in IUBK which are inducibly phosphorylated are lo-
cated within the N-terminal domain on residues S32 and S36
and mutation of these residues blocks signal induced degra-
dation [6^10]. A common target for inducing signals such as
TNFK or IL-1L is the NF-UB inducing kinase (NIK) [11]
which is directly upstream from the IUB kinase (IKK) [12].
Transmission of signals to IUBK appears to be facilitated by
the sca¡old proteins IKAP [13] and NEMO [14] or IKKQ [15]
which assemble the various molecules into a physically asso-
ciated signalling module. Speci¢c inhibition of the proteolytic
activity of the proteasome prevents NF-UB activation and
results in the accumulation of ubiquitinated forms of IUBK,
indicating that IUBK is targeted for degradation by a phos-
phorylation dependent ubiquitination process [10,16^18]. Mu-
tational analysis has indicated that K21 and K22 are the
primary sites for addition of multi-ubiquitination chains
with K38 and K47 as secondary sites [19^21]. Although signal
induced phosphorylation and ubiquitination of IUBK takes
place on the N-terminus of the protein deletion of the C-
terminus of IUBK renders the protein resistant to signal in-
duced degradation [7,22^24]. It is thought that the C-terminus
of IUBK functions post ubiquitination via interactions with the
catalytic core of the proteasome [25].
Ubiquitin addition is accomplished via a thioester cascade
with ubiquitin ¢rst being activated by a unique E1 enzyme
which utilises ATP to adenylate the C-terminal glycine of
ubiquitin. Release of AMP accompanies the formation of a
thioester bond between the C-terminus of ubiquitin and a
cysteine residue in the E1 protein. In a transesteri¢cation re-
action the ubiquitin is transferred from the ubiquitin activat-
ing enzyme to an E2 ubiquitin conjugating enzyme which
may, in turn, transfer the ubiquitin to an E3 ubiquitin protein
ligase. In many cases it is this enzyme which recognises the
protein substrate and catalyses formation of an isopeptide
bond between the C-terminus of ubiquitin and the O-amino
group of lysine in the target protein. Proteins destined for
degradation via the proteasome are coupled to multiple copies
of ubiquitin by formation of further isopeptide bonds between
additional ubiquitin molecules and lysine residues in the
bound ubiquitin [26]. Here we identify proteins required to
carry out polyubiquitination of phosphorylated IUBK. In the
presence of E1, cdc34 and a protein complex containing
LTrCP, Skp1 and Cul1 a phosphorylated peptide substrate,
representing residues 20^43 of IUBK, is e⁄ciently polyubiqui-
tinated.
2. Materials and methods
2.1. Expression constructs
cDNA encoding human LTrCP was obtained from R. Benarous
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(Paris). A modi¢ed form of LTrCP linked at its N-terminus to the
SV5 Pk epitope tag [27] was constructed by insertion of the LTrCP
coding sequence into a pcDNA3 construct containing the coding se-
quence of the tag [28]. A bacterial expression construct for 6-His
tagged cdc34 was obtained from R.J. Deshaies (Caltech). hUbc5
was obtained by PCR ampli¢cation of reverse transcribed mRNA
and was inserted into pGEX-2T. A baculovirus containing the coding
sequence for the human ubiquitin activating enzyme was obtained
from M. Rolfe (Mitotix).
2.2. Expression and puri¢cation of proteins
Ubiquitin activating enzyme was puri¢ed to homogeneity from ba-
culovirus infected insect cells by a⁄nity chromatography on ubiquitin
Sepharose essentially as described [29]. 6-His Cdc34 was puri¢ed from
induced bacteria by chromatography on Ni-agarose. Bound protein
was eluted with 250 mM Imidazole HCl pH 6.0, 5 mM betamercap-
toethanol and dialysed against 50 mM Tris-HCl pH 7.5, 200 mM
NaCl, 5 mM betamercaptoethanol. GST-Ubc5 was puri¢ed from in-
duced bacteria by chromatography on glutathione agarose. Bound
protein was eluted with reduced glutathione and cleaved with throm-
bin. After dialysis against 50 mM Tris-HCl pH 7.5, 200 mM NaCl,
5 mM betamercaptoethanol GST was removed from the Ubc5 by
passage through a column of glutathione agarose.
2.3. Preparation of cell extracts
COS7 cells were grown in 75 cm2 £asks in DMEM 10% FCS.
Transfections with the tagged LTrCP construct and pcDNA3 empty
vector were performed using lipofectamine as described [30]. Four to
six 75 cm2 £asks were used for each set of conditions. Where indicated
the proteasome inhibitor MG132 (20 WM) was added 45 min before
lysis while TNF (10 ng/ml) was added 15 min before lysis. Flasks were
washed twice with ice cold PBS then 0.4 ml of lysis bu¡er were added
to each £ask. The lysis bu¡er was 20 mM HEPES, pH 7.5, 0.5%
NP40, 1 M NDSB201 [31], 2 mM EDTA, 2 mM EGTA, 1 mM
DTT, 20 mM NaPO4 pH 7.5, 50 mM NaF, 5 mM sodium pyro-
phosphate, 1 mM sodium orthovanadate and 1 tablet ‘compete
mini’ protease inhibitor cocktail (Boehringer Mannheim) for 10 ml
of bu¡er. Following lysis extracts were centrifuged at 60 000Ug for
25 min at 4‡C. Ten Wl of protein A agarose (Pharmacia), to which
Mab 336 was crosslinked, was added to the supernatant (approx. 4 ml)
and tubes inverted for 2 h at 4‡C. Beads were collected by centrifu-
gation at 400Ug for 3 min and washed three times in PBS, 1 mM
DTT.
2.4. SDS-PAGE and immunoblotting
Immunoprecipitated proteins were fractionated on 10 or 15% poly-
acrylamide gels containing SDS. Anti-Skp1 antibody (Santa Cruz
Inc.) was used at a 1/2500 dilution in PBS containing 5% skimmed
milk, 0.5% Tween 20 and bound antibody detected with anti-rabbit-
HRP secondary antibody (1/2500, Amersham) and enhanced ECL
detection (Boehringer). Anti-Cul1 antibody [32] was a gift from Wil-
helm Krek and was used at 1/5000 dilution as described above. Mab
336 [27] was obtained from R.E. Randall. Mab 10B which recognises
IUBK was used as described [33].
2.5. Ubiquitination assays
The following peptide H3NLKKERLLDDRHDS(PO3H2)GLDS-
(PO3H2)MKDEEYE-COO3 was synthesised (Bio-Trend Germany),
and labelled with 125I (6U104 d.p.m./pmol) using the chloramine T
method as described [34]. Dephosphorylated peptide was obtained by
treatment of the radiolabelled peptide for 1 h at 37‡C with alkaline
phosphatase immobilised on beads (Sigma). Prior to addition, the
beads (20 Wl) were washed in 1 ml 0.1 M NaCl, 50 mM Tris pH
8.8, 1 mM MgCl2, 0.1 mM ZnCl2. Ubiquitination assays used 10 Wl
of beads to which the same volume of reaction mix was added. Prior
to addition the beads were washed once in reaction bu¡er. The reac-
tion mix was 0.1 M HEPES pH 7.5, 5 mM ATP, 10 mM MgCl2, 0.12
units/ml inorganic pyrophosphatase (EC 3.6.1.1) 4 Wg ubiquitin, 100
ng E1, 200 ng Cdc34 to which 3 ng of radiolabelled peptide was
added. Ubiquitination reactions were terminated and the products
analysed on 15% polyacrylamide gels containing SDS. Gels were ¢xed
in 10% w/v TCA, 40% v/v ethanol, 1% w/v glycerol, dried and exposed
to an image plate. The plate was scanned in a Fuji phosphorimager
1500 and radioactivity quantitated using MacBas software.
3. Results
3.1. The F-box protein LTrCP associates with phosphorylated
IUBK
LTrCP/Slimb is a conserved protein containing an F-box
and WD40 repeats. Related proteins are known to be involved
in the recognition of phosphorylated proteins which are des-
tined for ubiquitination and proteasome mediated degrada-
tion. To determine if LTrCP was involved in the targeting
of IUBK for signal induced ubiquitination a plasmid capable
of expressing a tagged version of LTrCP was introduced into
COS7 cells. Cells were either untreated, treated with TNF
alone or pretreated with the proteasome inhibitor MG132
then treated with TNF. Analysis of cell extracts by Western
blotting with antibody to IUBK indicates that, as expected,
IUBK is degraded in the presence of TNF, but in the presence
of TNF and MG132 the phosphorylated form accumulates
(Fig. 1B). When these same cell extracts were immunopreci-
pitated with the 336 anti-tag antibody prior to analysis by
Western blotting with an IUBK antibody only the more slowly
migrating, phosphorylated form of IUBK, which accumulates
in the presence of TNF and MG132, was shown to be asso-
ciated with LTrCP (Fig. 1B). Thus LTrCP appears to recog-
nise the phosphorylated form of IUBK.
3.2. LTrCP is part of an SCF complex containing Cdc53 and
Skp1
To determine if LTrCP was part of an SCF ubiquitin ligase
complex the tagged form of LTrCP was introduced in COS7
cells and cell extracts immunoprecipitated with the 336 anti-
tag antibody. Extracts of cells transfected with pcDNA3 were
used as control. Immunoprecipitated proteins were analysed
by Western blotting with antibodies to Skp1 or Cdc53. Both
Fig. 1. IUBK, phosphorylated after signal transduction, associates
with LTrCP. A: Diagrammatic representation of the tagged version
of LTrCP. B: COS7 cells were transfected with a construct express-
ing the tagged LTrCP and cells either treated with control medium
(^), TNF for 15 min or pretreated with MG132 for 45 min prior to
treatment with TNF for a further 15 min. Cell extracts were pre-
pared and immunoprecipitated with either Mab 336, which recog-
nises the tag on LTrCP or a control antibody Mab 214. Immuno-
precipitates were analysed by Western blotting with Mab 10B which
recognises IUBK. The positions of IUBK and the phosphorylated
form of IUBK are indicated.
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Skp1 (Fig. 2A) and Cdc53 (Fig. 2B) were immunoprecipitated
with the 336 anti-tag antibody, but were not detected in ex-
tracts from the pcDNA3 transfected cells. LTrCP is therefore
part of a multiprotein complex containing Skp1 and Cdc53.
3.3. The SCF complex containing LTrCP stimulates
ubiquitination of IUBK
To determine if the SCF complex containing LTrCP was
directly involved in the ubiquitination of phosphorylated
IUBK the tagged version of LTrCP was immunoa⁄nity puri-
¢ed from transfected COS7 cells which were either untreated,
treated with TNF alone or pretreated with the proteasome
inhibitor MG132 then treated with TNF. Western blotting
with the 336 anti-tag antibody revealed that LTrCP was de-
tected in all conditions, although the level of the protein was
elevated in the combined presence of TNF and MG132 (Fig.
3A). As a substrate for ubiquitination a peptide representing
residues 20^43 of IUBK was synthesised in which S32 and S36
were phosphorylated (Fig. 3C). The peptide was labelled with
125I and incubated with ubiquitin, ubiquitin activating enzyme
(E1), ubiquitin conjugating enzyme (E2) and the immunopuri-
¢ed LTrCP. In the presence of E1 and E2 alone mono- and di-
ubiquitinated forms of the peptide are detected. In the pres-
ence of immunopuri¢ed LTrCP from cells treated with TNF
and MG132 extensive polyubiquitination of the peptide sub-
strate is detected (Fig. 3B). LTrCP prepared from untreated or
TNF treated cells was less active in promoting polyubiquiti-
nation (Fig. 3B).
3.4. Requirements for LTrCP mediated ubiquitination of IUBK
In vivo it is well established that phosphorylation of S32
and S36 is a prerequisite for ubiquitination of IUBK. There-
fore to demonstrate the speci¢city of the in vitro reaction the
peptide was dephosphorylated and its substrate activity deter-
mined. In the presence of E1, E2 (Fig. 4B) and the immuno-
puri¢ed complex containing tagged LTrCP the phosphoryl-
ated peptide is e⁄ciently ubiquitinated, but this activity is
severely compromised when the peptide is dephosphorylated
(Fig. 4A). Based on electrophoretic mobility the activity re-
maining is likely to be a consequence of residual phospho-
rylated material which was not e⁄ciently dephosphorylated.
Although it has been reported that Ubc5 is the E2 responsible
for IUBK ubiquitination [35^37] many SCF complexes rely on
cdc34 to supply the E2 activity. To determine which E2 is
responsible for LTrCP mediated ubiquitination of the phos-
phorylated IUBK peptide, recombinant puri¢ed, ubc5 and
cdc34 were tested for activity. In the presence of immunopuri-
¢ed LTrCP and E1, cdc34 e⁄ciently catalyses the polyubiqui-
tination of the phosphorylated IUBK peptide, whereas ubc5
stimulated only mono- and di-ubiquitination (Fig. 4C). Con-
trol experiments demonstrated that in the presence of E1
Ubc5 and Cdc34 were both active in that they could form
thioesters with ubiquitin (data not shown). Thus it appears
that in the presence of an SCF complex containing LTrCP
cdc34 catalyses the phosphorylation dependent polyubiquiti-
nation of IUBK.
Fig. 2. LTrCP is associated with Skp1 and Cul1. Extracts from
COS7 cells transfected with either pcDNA3 or a construct express-
ing tagged LTrCP were immunoprecipitated with Mab 336 and the
immunoprecipitates analysed by Western blotting with antibodies to
either Skp1 or Cul1.
Fig. 3. Immunopuri¢ed LTrCP promotes polyubiquitination of a
phosphorylated peptide representing residues 20^43 of IUBK. COS7
cells were transfected with a construct expressing tagged LTrCP or
pcDNA3 and treated with TNF and MG132 as indicated. A: Ex-
pression of LTrCP was monitored by Western blotting with Mab
336. B: A 125I labelled, phosphorylated peptide representing residues
20^43 of IUBK was used as substrate for in vitro ubiquitination as-
says. In addition to substrate, assays contained ubiquitin, puri¢ed
E1, puri¢ed E2 (Cdc34) and immunoprecipitated tagged LTrCP iso-
lated from cells treated with TNF and MG132 as indicated. The po-
sitions of the phosphorylated peptide and ubiquitin adducts were in-
dicated. C: Structure of the phosphorylated IUBK peptide.
Fig. 4. Polyubiquitination of the IUBK peptide is mediated by
Cdc34 and requires phosphorylation on S32 and S36. A: 125I la-
belled, phosphorylated peptide was dephosphorylated by treatment
with immobilised alkaline phosphatase. Untreated or dephosphoryl-
ated peptides were used as substrates for ubiquitination either in the
presence or absence of ubiquitin and immunoprecipitated tagged
LTrCP as indicated. B: 125I labelled phosphorylated peptide was
used as substrate for in vitro ubiquitination in the presence of E1,
E2 (Cdc34) and immunoprecipitated tagged LTrCP as indicated. C:
Comparison of ubiquitinating activity of Cdc34 and Ubc5. 125I la-
belled phosphorylated peptide was used as substrate for in vitro
ubiquitination in the presence of E1, immunoprecipitated tagged
LTrCP and either Cdc34 or Ubc5 as indicated.
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4. Discussion
Activation of NF-UB proceeds via signal induced phospho-
rylation and ubiquitin mediated degradation of the IUBK in-
hibitor protein. Here we demonstrate that phosphorylated
IUBK is recognised by a multiprotein complex containing
LTrCP, Skp1 and Cdc53 and is polyubiquitinated by the E2
ubiquitin conjugating enzyme Cdc34. This conclusion is con-
sistent with a number of recent reports [35^39], but while
there is general agreement that LTrCP is involved in IUBK
ubiquitination there is less agreement on the E2 involved.
Here we demonstrate the role of Cdc34 in polyubiquitination
of a phosphorylated peptide representing residues 20^43 of
IUBK. This ubiquitination is strongly stimulated (15-fold) in
the presence of immunopuri¢ed LTrCP. An important di¡er-
ence in each of the studies is the substrate used in the assays.
While we have used puri¢ed peptide as substrate the previ-
ously published reports utilised full length IUBK which was
phosphorylated in vitro with preparations containing the IUB
kinase. The use of a peptide substrate along with puri¢ed
recombinant E1 and E2 and immunopuri¢ed complex con-
taining LTrCP permits the elimination of potentially interfer-
ing components and will facilitate biochemical analysis of the
ubiquitination reaction. It should be noted that under the
reaction conditions employed the ubiquitination reaction is
highly speci¢c in that dephosphorylated peptide does not act
as a substrate.
In addition to IUBK degradation LTrCP and its Drosophila
homologue Slimb are involved in the degradation of phos-
phorylated L-catenin [37,40] and CD4 associated with phos-
phorylated HIV-1 Vpu [41]. The F-box present in LTrCP con-
nects the bound substrate to Skp1, which is in turn bound to
Cdc53. Cdc53 and Skp1 are thus common components of
SCF complexes which derive their substrate recognition prop-
erties by recruitment of any one of a diverse array of F-box
containing proteins. In many cases SCF complexes containing
a variety of F-box proteins appear to utilise Cdc34 as the E2
for ubiquitination of the target protein and this is consistent
with our observation that Cdc34 is responsible for ubiquiti-
nation of phosphorylated IUBK.
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